Evidence map›Paper›PMID 40654626›Full record

ArticlebioRxiv : the preprint server for biology2025

Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.

Bruno Beernaert, Rose L Jady-Clark, Parin Shah, Erik Ramon-Gil, Nora M Lawson, Zack D Brodtman, Somnath Tagore, Frederik Stihler, Alfie S Carter, Shannique Clarke and 20 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors.

Bruno BeernaertDepartment of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0002-6219-6163
Rose L Jady-ClarkDepartment of Oncology, University of Oxford, Oxford, UK.
Parin ShahDepartment of Medicine, Division of Hematology and Medical Oncology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, USA.
Erik Ramon-GilFaculty of Medical Sciences, Newcastle University, Newcastle, UK.
Nora M LawsonDepartment of Neurosurgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Zack D BrodtmanDepartment of Medicine, Division of Hematology and Medical Oncology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, USA.
Somnath TagoreDepartment of Medicine, Division of Hematology and Medical Oncology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, USA.
Frederik StihlerDepartment of Medicine, Division of Hematology and Medical Oncology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, USA.
Alfie S CarterDepartment of Oncology, University of Oxford, Oxford, UK.
Shannique ClarkeDepartment of Oncology, University of Oxford, Oxford, UK.
Tong LiuDepartment of Oncology, University of Oxford, Oxford, UK.
Winston ZhuDepartment of Oncology, University of Oxford, Oxford, UK.
Erkin ErdalDepartment of Oncology, University of Oxford, Oxford, UK.
Alistair EastonDepartment of Oncology, University of Oxford, Oxford, UK.
Leticia CampoDepartment of Oncology, University of Oxford, Oxford, UK.
Molly BrowneDepartment of Oncology, University of Oxford, Oxford, UK.
Stephen AshLudwig Institute for Cancer Research, University of Oxford, Oxford, UK.
Nicola WaddellQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Thomas CrosbyVelindre Cancer Centre, Velindre Hospital, Cardiff, UK.
Simon R LordDepartment of Oncology, University of Oxford, Oxford, UK.
Derek A MannFaculty of Medical Sciences, Newcastle University, Newcastle, UK.
Ignacio MeleroCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Carlos E de AndreaDepartments of Pathology, Oncology and Immunology, Clínica Universidad de Navarra (CCUN), Pamplona, Spain.
Andréa E TijhuisEuropean Research Institute for the Biology of Ageing, University of Groningen, Groningen, The Netherlands.
Floris FoijerEuropean Research Institute for the Biology of Ageing, University of Groningen, Groningen, The Netherlands.
Ester M HammondDepartment of Oncology, University of Oxford, Oxford, UK.
Kadir C AkdemirDepartment of Neurosurgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jack LeslieFaculty of Medical Sciences, Newcastle University, Newcastle, UK.
Benjamin IzarDepartment of Medicine, Division of Hematology and Medical Oncology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, USA.
Eileen E ParkesDepartment of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0002-7855-3698

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Studying the evolution of drug resistance in prostate cancer at the single cell levelU54CA274506 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Peter Alan Sims · 2023 to 2026
$9.1M
Multi-cellular interactions defining the human brain metastatic nicheR01CA280414 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Benjamin Izar, Ashley Marie Laughney · 2023 to 2026
$2.8M
Mechanisms of liver metastasis and associated resistance to immunotherapyR37CA258829 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Benjamin Izar · 2021 to 2026
$2.6M
The role of the CD58:CD2 axis in cancer immune evasion and resistance to immunotherapyR01CA266446 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FRANGIEH, CHRISTOPHER · 2022 to 2025
$2.0M
NCI NIH HHS P30 CA013696NCI NIH HHS R01 CA266446NCI NIH HHS R01 CA280414NCI NIH HHS R37 CA258829NCI NIH HHS U54 CA274506Wellcome Trust
6 · The paper itself

Abstract

Chromosomal instability (CIN), a characteristic feature of esophageal adenocarcinoma (EAC), drives tumor aggressiveness and therapy resistance, presenting an intractable problem in cancer treatment. CIN leads to constitutive stimulation of the innate immune cGAS-STING pathway, which has been typically linked to anti-tumor immunity. However, despite the high CIN burden in EAC, the cGAS-STING pathway remains largely intact. To address this paradox, we developed novel esophageal cancer models, including a CIN-isogenic model, discovering myeloid-attracting chemokines - with the chemokine

Indexed as

cGASchemokineChromosomal instabilityesophagogastric cancermyeloidtumor microenvironment

Identifiers

PMID40654626
PMCPMC12248057

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.